This investigator proposes a comprehensive program for development as a clinical investigator which reflects her interest in pediatric clinical pharmacology and pediatric hematology/oncology. The long-term goal of this investigator is to understand how genetic polymorphisms affect the pathogenesis of sickle cell disease and response to treatment. Under the mentorship of well-established, nationally and internationally recognized experts in the areas of pharmacogenetics, pediatrics and pediatric sickle cell disease at Indiana University (IU), as well as collaboration with other experts in the fields of nitric oxide biology and sickle cell disease, this applicant will pursue a focused clinical research project related to the pharmacogenetics of pediatric sickle cell vaso-occlusive crisis and will receive both didactic and practical instruction in all aspects of clinical investigation through the IU K30 program. Painful vaso-occlusive crisis, the most common complication in children with sickle cell disease, exhibits a large amount of variability in clinical course and response to treatment that remains unexplained. This application addresses both the mechanisms involved in the pathogenesis of vaso-occlusive crisis as well as the pharmacologic barriers to successful treatment with hydroxyurea, a drug that targets disease pathogenesis.
Two specific aims will test the following hypotheses: (1) that genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene affect nitric oxide availability and the pathogenesis of vaso-occlusive crisis, and (2) that genetic variants influence the pharmacokinetics and pharmacodynamics of hydroxyurea. The results from these investigations will lead to additional research directed at establishing the link between disease pathogenesis and treatment in children with sickle cell disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23HL077684-05
Application #
7817141
Study Section
Special Emphasis Panel (ZHL1-CSR-M (O1))
Program Officer
Werner, Ellen
Project Start
2006-05-01
Project End
2011-10-30
Budget Start
2010-05-01
Budget End
2011-10-30
Support Year
5
Fiscal Year
2010
Total Cost
$142,012
Indirect Cost
Name
Children's Mercy Hosp (Kansas City, MO)
Department
Type
DUNS #
073067480
City
Kansas City
State
MO
Country
United States
Zip Code
64108
Estepp, Jeremie H; Wiczling, Pawe?; Moen, Joseph et al. (2017) Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure. Br J Clin Pharmacol :
Estepp, Jeremie H; Melloni, Chiara; Thornburg, Courtney D et al. (2016) Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. J Clin Pharmacol 56:298-306
Wiczling, Pawe?; Liem, Robert I; Panepinto, Julie A et al. (2014) Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease. J Clin Pharmacol 54:1016-22
Neville, Kathleen A; Szefler, Stanley J; Abdel-Rahman, Susan M et al. (2008) Single-dose pharmacokinetics of roflumilast in children and adolescents. J Clin Pharmacol 48:978-85